Top News

Chiesi Acquires Rare Diseases Company in $1.47 Billion Deal

January 11, 2023

Chiesi will acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in a deal worth up to $1.47 billion.

Ipsen to Bolster Liver Disease Portfolio with Albireo Acquisition

January 11, 2023

Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.

Merck Licenses Kelun-Biotech ADC’s in Deal Worth $9.3 Billion

January 04, 2023

Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.

GSK and Wave Life Sciences to Collaborate on Oligonucleotide Therapeutics

December 19, 2022

GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.

Amgen Inks $27.8 Billion Blockbuster to Acquire Horizon Therapeutics

December 13, 2022

Amgen’s $27.8 billion acquisition of Horizon Therapeutics, an Irish biotechnology company, is one of the largest of 2022.

Takeda to Purchase Autoimmune Treatment for $6 Billion

December 13, 2022

Takeda will purchase the rights to Nimbus Pharmaceuticals candidate, NDI-034858, which is currently being evaluated for treating multiple autoimmune diseases.

FDA Approves First Fecal Microbiota Product

December 07, 2022

Ferring Pharmaceuticals’ Rebyota was approved for the prevention of recurrence of Clostridioides difficile infection.

Eisai and BioGen Alzheimer’s Drug Shows Promising Results in Phase III Study

December 01, 2022

Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.

AstraZeneca Acquires Neogene Therapeutics for $320 Million

November 30, 2022

AstraZeneca inked a deal worth up to $320 million to purchase Neogene Therapeutics, a biotech start-up focused on T-cell receptor therapies.

FDA Approves $3.5 Million Hemophilia B Gene Therapy

November 28, 2022

CSL’s Hemgenix (etranacogene dezaparvovec) will cost approximately $3.5 million, making it the most expensive single-use medicine in the United States.